Page 52 - CIBERES-2015-eng

Research Groups
Group 9
Programme: Tuberculosis / Host-Pathogen Interactions Lead Researcher: Martín Montañés, Carlos
Group members
STAFF MEMBERS: Cebollada Solanas, Alberto | Lampreave Carrillo, Carlos.
ASSOCIATED MEMBERS: Aguiló Anento, Ignacio | Ainsa Claver, José Antonio | Días Rodrigues, Liliana Isabel | Gavín Benavent, Patricia | Gómez Aguirre, Ana Belén | Gómez Lus, Rafael | Gonzalo Asensio, Jesús | Gracia Díaz, Begoña | Ibarz Bosqued, Daniel | Iglesias Gozalo, MaJosé | Lafoz Pueyo, Carmen | Lezcano Carrera, Ma Antonia | Lucía Quintana, Ainhoa | Otal Gil, Isabel | Picó Marco, Ana | Revillo Pinilla, Ma José | Rubio Calvo, Ma Carmen | Samper Blasco, Sofía Luisa | Vitoria Agreda, Ma Asunción.
Main lines of research
Our Research Group on Mycobacterial Genetics has been working since 1992 in three lines of research funded by European and national research grants, being recognized as a leading group at the interna- tional level. Our current research interests are:
• Construction of New Vaccines against Tubercu- losis, focusing on genes implicated in the patho- genicity and virulence of M. tuberculosis. PI Carlos Martín.
• Molecular Epidemiology of Tuberculosis & Trans- position and Latency of M. tuberculosis focusing on the study of risk factors of transmission, and differences between strains of major epidemiologi- cal importance and the mechanism of slow growth of the Koch bacillus.PI Sofía Samper.
•Molecular Bases of Drug Resistance in Mycobacte- 52 I Annual report 2015 I CIBERES
ria, focusing on the contribution of efflux pumps to intrinsic drug resistance and in the discovery of novel antituberculosis compounds. PI José Anto- nio Ainsa
Altogether, our commitment is to study the com- plexity of M. tuberculosis by using a multidiscipli- nary approach and to work in coordination with oth- er national and international research groups.
Active Projects:
Line 1: • TBVAC H2020 643381 - H2020-PHC-2014 “Advancing novel and promising TB vaccine candi- dates from discovery to preclinical and early Clinical development” 2015-18 • BIO2014-52580-P “Inno- vando MTBVAC como vacuna contra la tuberculosis y nuevas aplicaciones terapéuticas en cáncer”. 2015- 18. • INNPACTO: Ref. IPT-2012-0327-090000 “Vacu-